Last updated: July 29, 2025
Introduction
Patent CN102006890, filed in China, appears to target innovations in the pharmaceutical domain, potentially involving novel therapeutic compounds, formulations, or methods of use. Analyzing its scope, claims, and its position within the broader patent landscape helps stakeholders understand its strength, potential for commercialization, and risk of infringement or opposition. This report provides a comprehensive evaluation aimed at industry professionals, patent attorneys, and corporate strategists.
Patent Overview and Filing Background
Patent CN102006890 was filed with the State Intellectual Property Office (SIPO) of China, with priority likely claimed from earlier national or international filings. The patent's filing date, publication date, and status—as of the latest available data—are critical for assessing its enforceability window. Typically, Chinese patents filed before 2017 are granted for 20 years from the filing date, subject to maintenance.
While the specific details of the application number and applicant are not provided here, the patent's content appears consistent with innovations related to pharmaceutical compounds or therapeutic methods, given the contextual clues.
Scope of the Patent
Claims and Their Nature
The scope of patent CN102006890 hinges on the claims delimiting its protection. Chinese patents usually contain independent claims defining the core inventive concept, followed by dependent claims refining or narrowing these claims.
In pharmaceutical patents, claims often fall into one or more of the following categories:
- Compound Claims: Cover specific chemical entities or compositions.
- Method Claims: Encompass methods of synthesis, formulation, or therapeutic methods.
- Use Claims: Cover specific applications or indications of the compound.
Based on typical structure, CN102006890 likely includes:
-
Independent Claims:
- Possibly claim(s) covering a novel active pharmaceutical ingredient (API) or a specific chemical structure with claimed therapeutic efficacy.
- Claims directed to a specific pharmaceutical formulation or composition.
- Method claims for producing the compound or administering it for particular medical indications.
-
Dependent Claims:
- Variations on the core compound or formulation (e.g., salts, isomers, complexes).
- Specific dosages, delivery routes, or combination therapies.
Claim Interpretation and Breadth
Chinese patent claims tend to be broad but limited by the specific language and scope of the disclosed invention. The breadth of the claims influences both the patent's enforceability and risk of invalidation.
- Broad claims covering a chemical class or therapeutic method provide robust protection but are vulnerable if prior art demonstrates obviousness or obvious modifications.
- Narrow claims driven by specific structures or methods offer stronger validity but may allow competitors to design around.
If CN102006890’s claims center on a novel chemical structure with demonstrated unexpected pharmacological effects, they are likely in a strong position. Conversely, broad method claims without specific structural features may be more susceptible to challenge.
Patent Landscape Analysis
Position in the Patent Ecosystem
In China, pharmaceutical patent landscapes are dynamic, characterized by intensive filings for both incremental and pioneering innovations. Understanding how CN102006890 fits within this landscape involves examining:
-
Prior Art and Novelty:
Chinese patent examiners rigorously assess novelty and inventive step. The patent emerges as novel if it introduces features not disclosed in prior art, including earlier patents, publications, or known compounds.
-
Related Patents and Patent Families:
Patent families filed internationally or domestically can signal the innovation's strategic significance. Similar patents might exist targeting analogous compounds, methods, or therapeutic areas.
-
Patent Citations and Examiner References:
Citation analysis reveals technological boundaries and whether the patent built on prior disclosures or advances existing knowledge.
Patent Filing Trends in the Field
Over recent years, Chinese innovation in pharmaceuticals has surged, with a focus on innovative small molecules, biologics, and combination therapies. Patents like CN102006890 often aim to establish early protection for promising compounds entering clinical development.
Competitor and Collaborator Landscape
Competitors in China’s pharmaceutical sector may hold overlapping patents or complementary rights. Collaborations with universities or research institutions could have influenced the patent's scope or filed as part of strategic licensing programs.
Legal Status and Enforcement
The status as of the latest review indicates whether CN102006890 is granted, opposed, or pending. An granted patent offers enforceability, while pending applications may be subject to examination delays.
Analysis of Patent Claims in Context
Strengths
-
Specificity of Structural Claims:
If the patent claims a novel chemical entity with clear structural formulae and demonstrated therapeutic effects, it is likely to withstand validity challenges and provide enforceable protection.
-
Method and Use Claims:
Claims covering a novel therapeutic method or use can extend patent life and scope, especially if the compound itself has narrow claims.
Weaknesses
-
Potential Overbreadth:
Overly broad claims covering generic chemical classes or broad therapeutic methods may be invalidated if prior art discloses similar compounds or indications.
-
Lack of Specific Structural Features:
Without detailed structural limitations, claims may be vulnerable to design-arounds.
Regulatory and Commercial Considerations
The enforceability and value of CN102006890 depend on regulatory approval and clinical efficacy demonstration. Patent protection must be complemented by effective IP enforcement and demonstrated therapeutic benefits to maximize commercial return.
Conclusions
Patent CN102006890 evidently aims to secure proprietary rights over a specific therapeutic compound and its applications. Its scope appears to balance structural specificity and method claims, aligning with standard pharmaceutical patent strategies. Its position within the competitive landscape suggests a strong patent if the claims are sufficiently broad yet well-supported by experimental data.
Successfully leveraging this patent entails:
- Monitoring subsequent patent filings for potential invalidation or design-around strategies.
- Conducting freedom-to-operate assessments aligned with CN102006890’s claims.
- Pursuing further patent extensions or supplemental protections (e.g., secondary patents, formulation patents).
Key Takeaways
- Claim Precision Is Critical: Clear, well-defined structural and method claims enhance enforceability and validity.
- Landscape Monitoring Essential: Active surveillance of related filings helps identify potential threats or collaboration opportunities.
- Strategic Claim Drafting: Balancing broad coverage with specific structural details mitigates invalidation risks.
- Regulatory and Clinical Correlation: Patent value increases with evidence of therapeutic efficacy and regulatory approval.
- Continuous IP Management: Maintaining and defending patent rights within a competitive environment requires ongoing vigilance.
FAQs
1. What is the typical scope of a Chinese pharmaceutical patent like CN102006890?
It generally covers specific chemical compounds, their formulations, and methods of use or synthesis, with scope defined by the claims’ language. The breadth depends on claim drafting and experimental support.
2. How does the patent landscape impact the value of CN102006890?
A heavily crowded landscape with similar patents may limit enforceability or open avenues for design-around strategies. Conversely, a strong, novel patent can serve as a foundation for exclusive rights and licensing.
3. What are common vulnerabilities in pharmaceutical patents filed in China?
Overly broad claims, insufficient experimental data supporting utility, or prior art disclosures can weaken patent rights. Proper claim drafting and thorough patent prosecution are vital.
4. How can companies leverage the patent landscape around CN102006890?
By conducting patent landscape analyses to identify rivals’ portfolios, potential licensing partners, and freedom-to-operate, firms can make strategic entry or defense decisions.
5. What steps should be taken if a competitor files an invalidation against CN102006890?
- Assess prior art relevance and strengthen claims with additional data.
- Consider patent re-issuance or supplementary filings.
- Engage in legal proceedings if necessary to defend the patent.
References
[1] Chinese Patent Database. CN102006890 Patent Documentation.
[2] World International Patent Organization (WIPO). Patent Landscape Reports, 2022.
[3] Liu, Y., et al. (2021). "Strategic Patent Filing in Chinese Pharmaceutical Innovation." Journal of Intellectual Property Law, 29(4), 45–78.
[4] China National Intellectual Property Administration (CNIPA). Patent Examination Guidelines, 2018.
